174 related articles for article (PubMed ID: 22293655)
21. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
Markova AA; Mihm U; Schlaphoff V; Lunemann S; Filmann N; Bremer B; Berg T; Sarrazin C; Zeuzem S; Manns MP; Cornberg M; Herrmann E; Wedemeyer H
PLoS One; 2014; 9(4):e94512. PubMed ID: 24751903
[TBL] [Abstract][Full Text] [Related]
22. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
23. Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy.
Kondo Y; Ueno Y; Ninomiya M; Tamai K; Tanaka Y; Inoue J; Kakazu E; Kobayashi K; Kimura O; Miura M; Yamamoto T; Kobayashi T; Igarashi T; Shimosegawa T
J Gastroenterol; 2012 Dec; 47(12):1323-35. PubMed ID: 22588246
[TBL] [Abstract][Full Text] [Related]
24. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
25. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.
Stinton LM; Myers RP; Coffin CS; Fritzler MJ
BMC Gastroenterol; 2013 Mar; 13():50. PubMed ID: 23506439
[TBL] [Abstract][Full Text] [Related]
26. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
Keppeke GD; Calise SJ; Chan EK; Andrade LE
World J Gastroenterol; 2016 Feb; 22(6):1966-74. PubMed ID: 26877604
[TBL] [Abstract][Full Text] [Related]
27. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV.
Slim J; Mildvan D; Han J; Korner E
J Int Assoc Provid AIDS Care; 2013; 12(5):354-62. PubMed ID: 23873217
[TBL] [Abstract][Full Text] [Related]
28. The relevance between anti-rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection.
Peker BO; Şener AG; Topal F; Sarıtaş Yüksel E
Microbiol Immunol; 2021 Apr; 65(4):171-177. PubMed ID: 33538354
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α.
Keppeke GD; Nunes E; Ferraz ML; Silva EA; Granato C; Chan EK; Andrade LE
PLoS One; 2012; 7(9):e45392. PubMed ID: 23028980
[TBL] [Abstract][Full Text] [Related]
30. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.
Nicot F; Alric L; Barange K; Métivier S; Dramard JM; Combis JM; Castan B; Meurisse JJ; Payen JL; Garipuy D; Desmorat H; Peron JM; Thebault S; Morin T; Renou C; Barel P; Guerin B; Imbert Y; Sire S; Sauné K; Chatelut E; Izopet J
J Med Virol; 2011 Mar; 83(3):437-44. PubMed ID: 21264864
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
32. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
33. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
34. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
van Leusen R; Adang RP; de Vries RA; Cnossen TT; Konings CJ; Schalm SW; Tan AC
Nephrol Dial Transplant; 2008 Feb; 23(2):721-5. PubMed ID: 18042614
[TBL] [Abstract][Full Text] [Related]
35. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
36. Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.
Kurosaki M; Hiramatsu N; Sakamoto M; Suzuki Y; Iwasaki M; Tamori A; Matsuura K; Kakinuma S; Sugauchi F; Sakamoto N; Nakagawa M; Yatsuhashi H; Izumi N
Antivir Ther; 2012; 17(1):35-43. PubMed ID: 22267467
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C.
Muratori P; Muratori L; Guidi M; Granito A; Susca M; Lenzi M; Bianchi FB
Clin Infect Dis; 2005 Feb; 40(4):501-7. PubMed ID: 15712070
[TBL] [Abstract][Full Text] [Related]
38. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
39. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.
Wang T; Blatt LM; Seiwert SD
J Interferon Cytokine Res; 2006 Jul; 26(7):473-83. PubMed ID: 16800786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
